Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by StockHawk1on Jan 12, 2023 2:56pm

94 Views

Post# 35219267

AGN DMT research featured in the Green Market Report

Algernon Pharmaceuticals (AGN.c AGNPF) is up on the CSE again today

The pharma development company was featured in The Green Market Report for its research on DMT for the treatment of stroke.

The article highlights how large this opportunity is for AGN, with the global stroke treatment market expected to reach $15B in 5 years. AGN itself values the psychedelic DMT research program at $20M.

IMO this article is required reading for anyone interested in investing in AGN as it details all the progress the company has made on this study so far, as well as AGN's future plans

https://www.greenmarketreport.com/algernon-pharmaceuticals-looks-to-advance-dmt-stroke-research/

<< Previous

Bullboard Posts

Next >>

How to trade on the stock market: A beginner’s guide